Sofía Granados-Romero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sofía Granados-Romero has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Esteban Zavaleta-Monestel
Hospital Pharmacy Section, International Pharmaceutical Federation, The Hague, ZH, The Netherlands
2 shared publications - Jeaustin Mora-Jiménez
Health Research Department, Clínica Bíblica, San José 1307-1000, Costa Rica
2 shared publications - José Andrés Castro-Gamboa
Pharmacy Department, University of Costa Rica, San José 11501-2060, Costa Rica
2 shared publications - José Miguel Chaverri-Fernández
Department of Pharmacy, University of Costa Rica, San Jose 11501-2060, Costa Rica
2 shared publications - Kevin Cruz-Mora
Pharmacy Department, Clínica Bíblica, San José 1307-1000, Costa Rica
2 shared publications - Luis Guillermo Herrera-Jiménez
Department of Pharmacy, University of Costa Rica, San Jose 11501-2060, Costa Rica
2 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (2) , 34
Correction: Zavaleta-Monestel et al. Sodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety. Kidney Dial. 2026, 6, 19
- 15 May 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (2) , 34
Open AccessCorrection: Zavaleta-Monestel et al. Sodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety. Kidney Dial. 2026, 6, 19
- Open Access
- 13 March 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (1) , 19
Sodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety
Objective: The objective of this study is to evaluate the efficacy and safety of sodium zirconium cyclosilicate in the treatment of hyperkalemia in adult patients based on the available scientific evidence. Methods: A systematic review of randomized controlled trials evaluating SZC in adult patients with hyperkalemia was conducted, including populations with chronic kidney disease and heart failure and patients undergoing hemodialysis. Outcomes assessed included serum potassium reduction, achievement and maintenance of normokalaemia, and adverse events. Results: Seven randomized controlled trials were included. SZC produced a rapid and significant reduction in serum potassium, with reductions of up to 1.28 mmol/L within 48 h and onset of action observed as early as 1–4 h. Across studies, 63–92% of patients achieved normokalaemia within 24–48 h, and maintenance therapy sustained normokalaemia for up to 28 days and longer in selected populations. The most frequently reported adverse events were mild-to-moderate edema and constipation, while hypokalemia was infrequent (<5% in most studies). Conclusions: Sodium zirconium cyclosilicate is an effective and generally well-tolerated option for the management of hyperkalemia, providing rapid potassium reduction and sustained normokalaemia. However, no randomized controlled trial included in this review demonstrated a significant benefit of SZC over comparators in major clinical outcomes—hospitalizations, cardiovascular events, or mortality; the evidence of clinical benefit is therefore absent from the current randomized trial literature.
- 13 March 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (1) , 19
Open AccessSodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety
Objective: The objective of this study is to evaluate the efficacy and safety of sodium zirconium cyclosilicate in the treatment of hyperkalemia in adult patients based on the available scientific evidence. Methods: A systematic review of randomized controlled trials evaluating SZC in adult patients with hyperkalemia was conducted, including populations with chronic kidney disease and heart failure and patients undergoing hemodialysis. Outcomes assessed included serum potassium reduction, achievement and maintenance of normokalaemia, and adverse events. Results: Seven randomized controlled trials were included. SZC produced a rapid and significant reduction in serum potassium, with reductions of up to 1.28 mmol/L within 48 h and onset of action observed as early as 1–4 h. Across studies, 63–92% of patients achieved normokalaemia within 24–48 h, and maintenance therapy sustained normokalaemia for up to 28 days and longer in selected populations. The most frequently reported adverse events were mild-to-moderate edema and constipation, while hypokalemia was infrequent (<5% in most studies). Conclusions: Sodium zirconium cyclosilicate is an effective and generally well-tolerated option for the management of hyperkalemia, providing rapid potassium reduction and sustained normokalaemia. However, no randomized controlled trial included in this review demonstrated a significant benefit of SZC over comparators in major clinical outcomes—hospitalizations, cardiovascular events, or mortality; the evidence of clinical benefit is therefore absent from the current randomized trial literature.